Metformin for Gestational Diabetes Mellitus: Progeny, Perspective, and a Personalized Approach
The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Abstract
Given the rapidly growing population of women diagnosed with gestational diabetes mellitus (GDM), approximating 1 in 7 pregnancies globally (1), in conjunction with the rising cost of insulins and lack of affordability (2), the popularity of using an oral agent such as metformin is expanding enormously. In fact, a number of organizations have supported its use as an alternative to insulin (3–6). However, recent long-term studies on offspring have provided conflicting results, with two of three studies recently published on the 4- to 9-year-old children of mothers with GDM or polycystic ovarian syndrome (PCOS) suggesting some long-term metabolic programming effects on the offspring (7–9). This has given some clinical investigators and organizations (10,11) pause in embracing metformin as equivalent to insulin (12–17). In the short term, there is an abundance of evidence that metformin has a safe track record and may have some benefits compared with insulin or glyburide when used for the treatment of GDM (18). Metformin is not teratogenic, with reassuring data for use in the first trimester (19–21), and in several meta-analyses, women with GDM randomized to metformin (often used with insulin) had less gestational weight gain, less gestational hypertension, and fewer infants who were large-for-gestational age (LGA) or with macrosomia (birth weight >4,000 g), and their infants had less neonatal hypoglycemia, than those randomized to insulin or glibenclamide (glyburide) therapy (22–24). However, metformin has a high failure rate, and 46% of women randomized to metformin needed to add insulin in the Metformin in Gestational Diabetes (MiG) randomized controlled trial (RCT) (25). In comparison, in a large multisite RCT in which insulin was compared with glyburide for GDM, the failure rate of glyburide was 18% (26). Important in interpreting RCT data is that glyburide …
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“None of the currently available human insulin preparations have been demonstrated to cross the placenta (93-98).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [95]
In the citing paper
“However, due to the potential for growth restriction or acidosis in the setting of placental insufficiency, metformin should not be used in pregnant people with hypertension or preeclampsia or those at risk for intrauterine growth restriction (90,95,96).”
From 15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024 (2024) · cites this paper as [95]
Citations
Cites
ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus
(2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002501 · Cited by 1,820
Metformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291 · cited 12×
“In a recent publication, investigators analyzed 182 offspring at 4 years of age (55% of the total cohort) from two RCTs of women with PCOS (8).”
BackgroundInfluentialHod, M., Kapur, A., Sacks, D. A., Hadar, E., Agarwal, M., Di Renzo, G. C., Roura, L. C., McIntyre, H. D., Morris, J. L., & Divakar, H. (2015) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(15)30033-3 · Cited by 767
15. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s015 · Cited by 504
Balsells, M., Garcia-Patterson, A., Sola, I., Roque, M., Gich, I., & Corcoy, R. (2015) · BMJ · doi:10.1136/bmj.h102 · Cited by 498
Metformin versus placebo in obese pregnant women without diabetes mellitus
Syngelaki, A., Nicolaides, K. H., Balani, J., Hyer, S., Akolekar, R., Kotecha, R., Pastides, A., & Shehata, H. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509819 · Cited by 394
Metformin in Gestational Diabetes: The Offspring Follow-Up (MiG TOFU)
Rowan, J. A., Rush, E. C., Obolonkin, V., Battin, M., Wouldes, T., & Hague, W. M. (2011) · Diabetes Care · doi:10.2337/dc11-0660 · Cited by 379 · cited 1×
“No measure of visceral fat was given (45) and no differences were found in neurodevelopmental outcomes.”
BackgroundThompson, D., Berger, H., Feig, D., Gagnon, R., Kader, T., Keely, E., Kozak, S., Ryan, E., Sermer, M., & Vinokuroff, C. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.044 · Cited by 377
Self-citationFeig, D. S., Berger, H., Donovan, L., Godbout, A., Kader, T., Keely, E., & Sanghera, R. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.038 · Cited by 344
Self-citationVanky, E., Stridsklev, S., Heimstad, R., Romundstad, P., Skogøy, K., Kleggetveit, O., Hjelle, S., von Brandis, P., Eikeland, T., Flo, K., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0853 · Cited by 315
Rowan, J. A., Rush, E. C., Plank, L. D., Lu, J., Obolonkin, V., Coat, S., & Hague, W. M. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000456 · Cited by 305
Chiswick, C., Reynolds, R. M., Denison, F., Drake, A. J., Forbes, S., Newby, D. E., Walker, B. R., Quenby, S., Wray, S., Weeks, A., et al. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00219-3 · Cited by 260
Romero, R., Erez, O., Hüttemann, M., Maymon, E., Panaitescu, B., Conde-Agudelo, A., Pacora, P., Yoon, B. H., & Grossman, L. I. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.06.003 · Cited by 253 · cited 1×
“Interestingly, some data suggest that metformin may, in part, prevent the development of preeclampsia potentially by improving angiogenesis (34,35).”
BackgroundPowe, C. E., Allard, C., Battista, M.-C., Doyon, M., Bouchard, L., Ecker, J. L., Perron, P., Florez, J. C., Thadhani, R., & Hivert, M.-F. (2016) · Diabetes Care · doi:10.2337/dc15-2672 · Cited by 240 · cited 1×
“are not all effectively targeted by the same agent (50).”
BackgroundHanem, L. G. E., Stridsklev, S., Júlíusson, P. B., Salvesen, Ø., Roelants, M., Carlsen, S. M., Ødegård, R., & Vanky, E. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02419 · Cited by 199
Butalia, S., Gutierrez, L., Lodha, A., Aitken, E., Zakariasen, A., & Donovan, L. (2017) · Diabetic Medicine · doi:10.1111/dme.13150 · Cited by 170
The emerging role of mTORC1 signaling in placental nutrient-sensing
Jansson, T., Aye, I. L. M. H., & Goberdhan, D. C. I. (2012) · Placenta · doi:10.1016/j.placenta.2012.05.010 · Cited by 166
Treatments for gestational diabetes: A systematic review and meta-analysis
Farrar, D., Simmonds, M., Bryant, M., Sheldon, T. A., Tuffnell, D., Golder, S., & Lawlor, D. A. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-015557 · Cited by 163
Insulin for the treatment of women with gestational diabetes
Brown, J., Grzeskowiak, L., Williamson, K., Downie, M. R., & Crowther, C. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012037.pub2 · Cited by 158 · cited 1×
“erence, availability, severity of GDM, and dosing practices (30,31).”
BackgroundGiven, J. E., Loane, M., Garne, E., Addor, M.-C., Bakker, M., Bertaut-Nativel, B., Gatt, M., Klungsoyr, K., Lelong, N., Morgan, M., et al. (2018) · BMJ · doi:10.1136/bmj.k2477 · Cited by 130
Metformin use in pregnancy: promises and uncertainties
Lindsay, R. S., & Loeken, M. R. (2017) · Diabetologia · doi:10.1007/s00125-017-4351-y · Cited by 127 · cited 3×
“(33), and it should not be used if the fetus is at risk for an ischemic environment including placental insufficiency, hypertension, preeclampsia, or growth restriction (12,13,15,16).”
BackgroundJiang, Y.-F., Chen, X.-Y., Ding, T., Wang, X.-F., Zhu, Z.-N., & Su, S.-W. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4403 · Cited by 124
Nachum, Z., Zafran, N., Salim, R., Hissin, N., Hasanein, J., Gam Ze Letova, Y., Suleiman, A., & Yefet, E. (2017) · Diabetes Care · doi:10.2337/dc16-2307 · Cited by 118 · cited 1×
“Combining metformin and glyburide has been reported, but use of two agents that cross the placenta and may have programming effects of unknown longterm consequence (53) should be limited to circumstances when insulin is not a”
BackgroundRisk of pre‐eclampsia in women taking metformin: a systematic review and meta‐analysis
Alqudah, A., McKinley, M. C., McNally, R., Graham, U., Watson, C. J., Lyons, T. J., & McClements, L. (2018) · Diabetic Medicine · doi:10.1111/dme.13523 · Cited by 114
Sénat, M.-V., Affres, H., Letourneau, A., Coustols-Valat, M., Cazaubiel, M., Legardeur, H., Jacquier, J. F., Bourcigaux, N., Simon, E., Rod, A., et al. (2018) · JAMA · doi:10.1001/jama.2018.4072 · Cited by 114
Metformin in the management of diabetes during pregnancy and lactation
Priya, G., & Kalra, S. (2018) · Drugs in Context · doi:10.7573/dic.212523 · Cited by 101 · cited 3×
“(33), and it should not be used if the fetus is at risk for an ischemic environment including placental insufficiency, hypertension, preeclampsia, or growth restriction (12,13,15,16).”
BackgroundA cautionary response to SMFM statement: pharmacological treatment of gestational diabetes
Barbour, L. A., Scifres, C., Valent, A. M., Friedman, J. E., Buchanan, T. A., Coustan, D., Aagaard, K., Thornburg, K. L., Catalano, P. M., Galan, H. L., et al. (2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2018.06.013 · Cited by 101 · cited 4×
“(33), and it should not be used if the fetus is at risk for an ischemic environment including placental insufficiency, hypertension, preeclampsia, or growth restriction (12,13,15,16).”
BackgroundInfluentialSelf-citationDodd, J. M., Louise, J., Deussen, A. R., Grivell, R. M., Dekker, G., McPhee, A. J., & Hague, W. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30310-3 · Cited by 99
Oral anti-diabetic pharmacological therapies for the treatment of women with gestational diabetes
Brown, J., Martis, R., Hughes, B., Rowan, J., & Crowther, C. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011967.pub2 · Cited by 95 · cited 1×
“erence, availability, severity of GDM, and dosing practices (30,31).”
BackgroundSMFM statement: pharmacological treatment of gestational diabetes
(2018) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2018.01.041 · Cited by 94
Predictors of glyburide failure in the treatment of gestational diabetes
Kahn, B. F., Davies, J. K., Lynch, A. M., Reynolds, R. M., & Barbour, L. A. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000218704.28313.36 · Cited by 85 · cited 1×
“30 years), and a previous history of GDM (51,52).”
BackgroundSelf-citationGrowth, body composition and metabolic profile of 8-year-old children exposed to metformin in utero
Rø, T. B., Ludvigsen, H. V., Carlsen, S. M., & Vanky, E. (2012) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365513.2012.712319 · Cited by 85 · cited 1×
“women with PCOS treated with metformin versus placebo, the offspring of mothers treated with metformin weighed more at 1 year of age (46), and in a small, very limited study of 25 offspring followed at 8 years of age, higher fasting glucoses and a trend to higher systolic blood pressures were seen in the metforminexpo…”
BackgroundMetformin's Effect on First-Year Weight Gain: A Follow-up Study
Carlsen, S. M., Martinussen, M. P., & Vanky, E. (2012) · Pediatrics · doi:10.1542/peds.2012-0346 · Cited by 83 · cited 1×
“women with PCOS treated with metformin versus placebo, the offspring of mothers treated with metformin weighed more at 1 year of age (46), and in a small, very limited study of 25 offspring followed at 8 years of age, higher fasting glucoses and a trend to higher systolic blood pressures were seen in the metforminexpo…”
BackgroundBarbour, L. A., Farabi, S. S., Friedman, J. E., Hirsch, N. M., Reece, M. S., Van Pelt, R. E., & Hernandez, T. L. (2018) · Obesity · doi:10.1002/oby.22246 · Cited by 74
Self-citationMetformin from mother to unborn child-are there unwarranted effects?
Nguyen, L., Chan, S.-Y., & Teo, A. K. K. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.047 · Cited by 67 · cited 3×
“(33), and it should not be used if the fetus is at risk for an ischemic environment including placental insufficiency, hypertension, preeclampsia, or growth restriction (12,13,15,16).”
Backgroundon behalf of the MiTy Collaborative Group, Feig, D. S., Murphy, K., Asztalos, E., Tomlinson, G., Sanchez, J., Zinman, B., Ohlsson, A., Ryan, E. A., Fantus, I. G., et al. (2016) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-016-0954-4 · Cited by 65
Self-citationLandi, S. N., Radke, S., Engel, S. M., Boggess, K., Stürmer, T., Howe, A. S., & Funk, M. J. (2019) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2018.4214 · Cited by 64
Dodd, J. M., Grivell, R. M., Deussen, A. R., & Hague, W. M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010564.pub2 · Cited by 56
Effect of pregnancy on the pharmacokinetics of metformin
Hughes, R. C. E., Gardiner, S. J., Begg, E. J., & Zhang, M. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01769.x · Cited by 54 · cited 1×
“, and the concentrations of metformin and glyburide in pregnant women are ;80% and ;50%, respectively, of those in nonpregnant women due to increased clearance (28,29).”
Backgroundvan Weelden, W., Wekker, V., de Wit, L., Limpens, J., Ijäs, H., van Wassenaer-Leemhuis, A. G., Roseboom, T. J., van Rijn, B. B., DeVries, J. H., & Painter, R. C. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0479-0 · Cited by 51 · cited 7×
“Further, there were no differences in behavioral assessments in offspring at 4 years of age after adjustment for maternal age, race/ethnicity, socioeconomic status, BMI, smoking, history of GDM, and timing of GDM diagnosis and treatment (9).”
BackgroundInfluentialA pharmacologic approach to the use of glyburide in pregnancy
Caritis, S. N., & Hebert, M. F. (2013) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31829007f0 · Cited by 41 · cited 2×
“, and the concentrations of metformin and glyburide in pregnant women are ;80% and ;50%, respectively, of those in nonpregnant women due to increased clearance (28,29).”
BackgroundHenry, R. R., Frías, J. P., Walsh, B., Skare, S., Hemming, J., Burns, C. M., Bicsak, T. A., Baron, A., & Fineman, M. S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0203946 · Cited by 35 · cited 1×
“glucose levels even when not absorbed (12,13,15,16), supporting the further testing of poorly absorbed preparations to reduce glucose while minimizing fetal exposure (49).”
BackgroundOral Agents for the Treatment of Gestational Diabetes
Finneran, M. M., & Landon, M. B. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1093-2 · Cited by 34
Valdés, E., Sepúlveda‐Martínez, A., Candia, P., Abusada, N., Orellana, R., Manukian, B., & Cuellar, E. (2018) · Journal of Obstetrics and Gynaecology Research · doi:10.1111/jog.13477 · Cited by 29
Barrett, H. L., Dekker Nitert, M., Jones, L., O’Rourke, P., Lust, K., Gatford, K. L., De Blasio, M. J., Coat, S., Owens, J. A., Hague, W. M., et al. (2013) · Diabetes Care · doi:10.2337/dc12-2132 · Cited by 28 · cited 1×
“(33), and it should not be used if the fetus is at risk for an ischemic environment including placental insufficiency, hypertension, preeclampsia, or growth restriction (12,13,15,16).”
BackgroundPregnancy outcome after first-trimester exposure to metformin: A prospective cohort study
Scherneck, S., Schlinke, N., Beck, E., Grupe, K., Weber-Schoendorfer, C., & Schaefer, C. (2018) · Reproductive Toxicology · doi:10.1016/j.reprotox.2018.07.004 · Cited by 28
Predictors of metformin failure in gestational diabetes mellitus (GDM)
Khin, M. O., Gates, S., & Saravanan, P. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.01.003 · Cited by 24 · cited 1×
“30 years), and a previous history of GDM (51,52).”
BackgroundNovel therapies for diabetes mellitus in pregnancy
Feghali, M. N., & Scifres, C. (2018) · BMJ · doi:10.1136/bmj.k2034 · Cited by 17
Insulin vs Glyburide for Gestational Diabetes
Coustan, D. R., & Barbour, L. A. (2018) · JAMA · doi:10.1001/jama.2018.4561 · Cited by 9 · cited 1×
“RCT data is that glyburide was often not dosed according to its pharmacokinetic properties given the insulin peak from glyburide does not occur until 3–4 h after dosing, similar to regular insulin (13,27).”
BackgroundSelf-citationBarbour, L. A., Pelt, R. E. V., Brumbaugh, D. E., Hernandez, T. L., & Friedman, J. E. (2012) · Diabetes Care · doi:10.2337/dc11-2107 · Cited by 6
Self-citationBarbour, L. A., & Davies, J. K. (2017) · Diabetes Care · doi:10.2337/dc17-0554 · Cited by 6
Self-citation
Research works printed but not linked: 1
- American Diabetes Association, 2018, 13. Management of diabetes in pregnancy: Standards of Medical Care in Diabetes—2018, Diabetes Care, 41
Cited by
McIntyre, H. D., Catalano, P., Zhang, C., Desoye, G., Mathiesen, E. R., & Damm, P. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0098-8 · Cited by 1,850
15. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s015 · Cited by 504
14. Management of Diabetes in Pregnancy:Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s014 · Cited by 381
15. Management of Diabetes in Pregnancy:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s015 · Cited by 284
14. Management of Diabetes in Pregnancy:Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s014 · Cited by 268
Metadata
- Authors
- Barbour, L. A., & Feig, D. S.
- Affiliations
- University of Colorado Anschutz (US)
- University of Toronto (CA)
- Corresponding author
- Barbour, Linda A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-02-12
- Volume
- 42
- Issue
- 3
- Pages
- 396-399
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2915607850
- Cited by
- 44
- References
- 52
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 6 · 2023: 5 · 2022: 4 · 2021: 11 · 2020: 7 · 2019: 5
- FWCI
- 7.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- metformin, gestational diabetes mellitus, insulin therapy, glibenclamide, offspring metabolic programming, polycystic ovary syndrome, teratogenicity, gestational weight gain, macrosomia, neonatal hypoglycemia, personalized treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.